Rheumatology Practice Management October 2017 Vol 5 No 5
In a recent interview, Ms Zlatkus shared comments about her aspirations as President of NORM and Editor-in-Chief of RPM.
In a breakout session, Jennifer Cosey, Principal and Senior Consultant, Eagle Associates, Ann Arbor, MI, discussed issues related to the HIPAA Privacy, Security, and Breach Notification Rules, including how to assess a potential breach of protected health information (PHI) and determine whether the breach is reportable.
According to Ms Skolnik, the appointment of Dr Gottlieb as the new FDA Commissioner may provide some semblance of stability to the FDA amidst potentially radical changes.
Before we get too excited, let us look at the history of the E&M documentation guidelines, because this may hold a clue as to how CMS will approach revisions to these guidelines. It is worthwhile to note that CMS’ previous attempts to revise the E&M documentation guidelines were met with a lack of consensus and support from stakeholders.
The following clinical trials represent a selection of key studies that are currently recruiting patients with lupus for inclusion in investigations of new therapies and new regimens of existing treatments for individuals with the disease.
You may know by now that the Centers for Medicare & Medicaid Services created Healthcare Common Procedure Coding System (HCPCS) code Q5102 to be used when reporting “Injection, infliximab, biosimilar, 10 mg.” The October 2017 HCPCS update included a new modifier, ZC Merck/Samsung Bioepis, to be used with HCPCS code Q5102.
Results 1 - 6 of 6